Abbott Announces Commercial Availability Of Oncodetect Molecular Residual Disease Test
Benzinga Newsdesk 3 weeks ago
News
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Abbott (NYSE: ABT) today announced the commercial availability of its next-generation Oncodetect® MRD test, a personalized, tumor-informed, whole-genome sequencing test designed to provide molecular insights during and
Abbott (NYSE: ABT) today announced the commercial availability of its next-generation Oncodetect® MRD test, a personalized, tumor-informed, whole-genome sequencing test designed to provide molecular insights during and after cancer treatment.
